Gain Therapeutics is ready to share the latest R&D update on Parkinson’s Disease. This event is intended for all KOL’s, Analysts, Patient Advocates, and investors who share a common interest in neurodegenerative diseases.
“Beyond Symptomatic Treatment of #Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
This R&D update event will occur Thursday, February 22nd, 2024 between 11:00 am – 12:00 pm EST.
Registration information can be found here: https://lnkd.in/erx-c4vn
Participants are encouraged to send questions to ir@gaintherapeutics.com. These questions will be answered during the Q&A portion of the event.
Discussion Topics will include:
- GBA-Associated Parkinson’s Disease & Other Synucleinopathies: current unmet medical needs and the therapies we need for them.
- From Biology to Classification: Understanding Parkinson’s Disease
A discussion of the recent in vivo data for GT-02287 as the best-in-class small molecule for the treatment of GBA-Parkinson’s DIsease and other neurodegenerative diseases.
Speakers: Featured speakers for this event will be Gain Therapeutics’ Matthias Alder, CEO, and Joanne Taylor, SVP Research.
Key Opinion Leaders: The event will also host two Key Opinion Leaders, Professor Roy Alcalay of Columbia University and Professor Tiago Fleming Outeiro of University Medical Center Göttingen.
Professor Alcalay is the current Chief of the Movement Disorders Divisions at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. He is also an associate professor of clinical neurology at Columbia University. His research focuses on biomarkers and genetics in Parkinson’s Disease. Additionally, Professor Alcalay is a member of The Michael J. Fox Foundation for Parkinson’s Research-funded Parkinson’s Progression Markers Initiative (PPMI) executive steering committee, and the PI of the Parkinson’s Foundation-funded PD GENEration study.
Professor Outeiro is the Professor and Director of the Department of Experimental Neurodegeneration at the University Medical Center Göttingen in Germany. He is also a Professor at Newcastle University. His research focuses on understanding the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease. He is also Chair of the Task Force on the Biological Definition of Parkinson’s Disease of International Parkinson and Movement Disorder Society.
